ImmunoPrecise Antibodies Ltd. Files 6-K with Meeting Notice
Ticker: HYFT · Form: 6-K · Filed: Sep 23, 2024 · CIK: 1715925
Sentiment: neutral
Topics: 6-K, shareholder-meeting, corporate-governance
TL;DR
IPA files 6-K, shareholders meeting notice attached. Get ready for updates.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on September 23, 2024, reporting for the month of September 2024. The filing includes a Notice of Annual General and Special Meeting dated September 23, 2024, as Exhibit 99.1. Kristin Taylor, Chief Financial Officer, signed the report.
Why It Matters
This filing indicates upcoming corporate governance activities, including an annual general and special meeting, which are important for shareholders to stay informed about company decisions.
Risk Assessment
Risk Level: low — This is a routine filing for a 6-K, primarily containing a notice of a shareholder meeting, and does not disclose significant new financial or operational information.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- Kristin Taylor (person) — Chief Financial Officer
- September 23, 2024 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer filed for the month of September 2024, and it includes a Notice of Annual General and Special Meeting as an exhibit.
Who signed the Form 6-K on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor, Chief Financial Officer, signed the report on behalf of ImmunoPrecise Antibodies Ltd.
What is the filing date of this report?
The filing date of this report is September 23, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
What exhibit is included with this filing?
Exhibit 99.1, a Notice of Annual General and Special Meeting dated September 23, 2024, is included with this filing.
Filing Stats: 162 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2024-09-23 14:40:14
Filing Documents
- form6k.htm (6-K) — 5KB
- exhibit99-1.htm (EX-99.1) — 5KB
- 0001062993-24-016889.txt ( ) — 11KB
From the Filing
ImmunoPrecise Antibodies Ltd.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 . Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: September 23, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer EXHIBIT INDEX 99.1 Notice of Annual General and Special Meeting dated September 20, 2024